NASDAQ:SXTP 60 Degrees Pharmaceuticals Q1 2026 Earnings Report $1.16 +0.12 (+11.54%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.10 -0.06 (-5.52%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast 60 Degrees Pharmaceuticals EPS ResultsActual EPS-$1.28Consensus EPS -$0.76Beat/MissMissed by -$0.52One Year Ago EPSN/A60 Degrees Pharmaceuticals Revenue ResultsActual Revenue$0.16 millionExpected Revenue$0.44 millionBeat/MissMissed by -$272.91 thousandYoY Revenue GrowthN/A60 Degrees Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time7:00AM ETUpcoming Earnings60 Degrees Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) 60 Degrees Pharmaceuticals Earnings HeadlinesHead to Head Analysis: Canopy Growth (NASDAQ:CGC) vs. 60 Degrees Pharmaceuticals (NASDAQ:SXTP)September 21 at 5:44 AM | americanbankingnews.comHead-To-Head Comparison: 60 Degrees Pharmaceuticals (NASDAQ:SXTP) vs. Innoviva (NASDAQ:INVA)September 18, 2026 | americanbankingnews.comNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.September 24 at 1:00 AM | Behind the Markets (Ad)60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3, 2026 | globenewswire.com60 Degrees Pharmaceuticals Announces Second Quarter 2026 ResultsAugust 14, 2026 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq RulesJuly 30, 2026 | globenewswire.comSee More 60 Degrees Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email. Email Address About 60 Degrees Pharmaceuticals60 Degrees Pharmaceuticals (NASDAQ:SXTP), Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments designed to address significant unmet medical needs, including diseases that affect travelers, military personnel and populations in tropical or underserved regions. The company’s principal product is Arakoda (tafenoquine), an antimalarial approved by the U.S. Food and Drug Administration for the prevention of malaria in adults. Arakoda is intended for use by individuals traveling to or living in areas where malaria is present and is marketed in the United States. 60 Degrees Pharmaceuticals is also evaluating tafenoquine for additional potential applications, including babesiosis, a tick-borne disease found primarily in the United States. The company is headquartered in Washington, D.C., and is led by Chief Executive Officer Geoffrey Dow.View 60 Degrees Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
